Aximin 200 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Rifaximin |
| Company | Acme laboratories ltd |
| Also available as |
Indications
- Treatment of traveler's diarrhea by noninvasive strains of E. coli
- Reduction in risk of overt hepatic encephalopathy
- Bacterial overgrowth of irritable bowel syndrome
Pharmacology
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic. It inhibits bacterial RNA synthesis by its action on the beta-subunit of the DNA-dependent RNA polymerase. It shows broad spectrum activity against many species of Gram-positive and Gram-negative, aerobic and anaerobic bacteria.
Dosage & Administration
- For traveler's diarrhea: 200 mg 3 times daily for 3 days (patients ≥12 years of age)
- For hepatic encephalopathy: 550 mg 2 times daily (patients ≥18 years of age)
- For bacterial overgrowth of irritable bowel syndrome: 400 mg 3 times daily for 10 days or 550 mg 3 times daily for 14 days
Interaction
In vitro study suggests that Aximin induces CYP3A4. However, in patients with normal liver function, Aximin at the recommended dosing regimen is not expected to induce CYP3A4.
Contraindications
Hypersensitivity to Rifaximin or any of the rifamycin antimicrobial agents
Side Effects
- Flatulence
- Headache
- Abdominal pain
- Rectal tenesmus
- Defecation urgency
- Nausea
- Constipation
- Pyrexia
- Vomiting
- Reactions including anaphylaxis, angioneurotic edema, and exfoliative dermatitis
Pregnancy & Lactation
Pregnancy category C. It is not known whether Rifaximin is excreted in human milk.
Precautions & Warnings
- Not effective in patients with diarrhea complicated by fever and/or blood in the stools
- Discontinue if diarrhea symptoms worsen or persist for more than 24-48 hours
- Consider alternative antibiotic therapy if needed
- Pseudomembranous colitis has been reported with nearly all antibacterial agents
Use in Special Populations
- Renal Impairment: Pharmacokinetics in patients with impaired renal function has not been studied
- Hepatic Impairment: Systemic exposure of Aximin elevated in patients with hepatic impairment
Overdose Effects
No specific information available on the treatment of overdose with Aximin. Discontinue Aximin, treat symptomatically, and institute supportive measures as required.
Therapeutic Class
4-Quinolone preparations
Storage Conditions
Keep below 30°C, away from light & moisture. Keep out of the reach of children.